Papillary renal cell carcinoma (PRCC) is a distinct and significant form of kidney cancer that originates in the kidney’s tiny filtering tubes known as tubules. Though it represents just 15% to 20% of renal cell carcinoma (RCC) cases, which themselves constitute roughly 90% of kidney cancers, PRCC deserves focused attention due to its unique biological behavior and treatment challenges. Unlike the more prevalent clear cell RCC (ccRCC), PRCC is categorized as a non-clear cell type and exhibits characteristic growths called papillae—small, finger-like projections that define its pathology under the microscope.
Importantly, PRCC comes in two subtypes: Type 1 and Type 2. Type 1 is the more common and generally more indolent form, progressing slowly and offering a comparatively favorable prognosis. In stark contrast, Type 2 is less common but far more aggressive, often leading to rapid disease advancement and poorer outcomes. This dichotomy adds complexity to managing the disease and underscores the need for tailored therapeutic approaches.
Challenges in Detection and Patient Experience
One of the silent hurdles with PRCC is its often asymptomatic early stages. Many patients may remain unaware of their condition until routine imaging or incidental findings reveal suspicious kidney masses. When symptoms do present, they are typically nonspecific—flank pain, hematuria (blood in the urine), or abdominal discomfort—mirroring many other benign or malignant kidney conditions. This symptom overlap can delay diagnosis, underscoring the critical importance of vigilance among healthcare providers and patients alike.
Although no preventative measures exist for PRCC per se, mitigating modifiable risk factors can reduce the odds of kidney cancer overall. These include smoking cessation, maintaining healthy body weight, controlling hypertension, and managing occupational exposures. However, given that genetics and random mutations significantly contribute to PRCC pathogenesis, even optimal lifestyle choices cannot guarantee prevention.
Diagnosis: More Than Just Imaging
Diagnosing PRCC relies heavily on a combination of medical history review, clinical examination, and advanced imaging techniques. CT scans and MRIs remain instrumental in detecting kidney masses, but radiologic appearances alone cannot definitively differentiate PRCC from other RCC types. Thus, tissue biopsy and histopathological analysis become indispensable. PRCC cells classically absorb certain dyes, appearing pink under microscopic examination, aiding pathologists in confirming the diagnosis and identifying the subtype—a crucial step for treatment planning.
Interestingly, the molecular biology of PRCC is rapidly unfolding, revealing that particular genetic alterations, such as mutations in the MET gene, drive tumor growth. This knowledge is not only pivotal for understanding disease mechanisms but has direct therapeutic implications, as we discuss next.
Current and Emerging Treatments: A Landscape in Flux
The cornerstone of PRCC treatment remains surgery. Depending on tumor size, location, and extent, a surgeon may perform partial nephrectomy (removing the tumor and part of the kidney) or radical nephrectomy (removing the entire kidney along with adjacent tissues and lymph nodes). Surgery can be curative in localized PRCC but may not always be feasible, especially in advanced or metastatic cases.
Radiation therapy and immunotherapy have roles primarily as adjunct or palliative treatments, given PRCC’s relative radioresistance and the variable responses to immune checkpoint inhibitors (ICIs). Traditional chemotherapy, often effective in other cancers, is generally less impactful for PRCC, pushing clinicians to explore targeted therapies and innovative modalities.
Here is where recent advancements become truly exciting. Targeted therapies aiming at the MET pathway—particularly MET tyrosine kinase inhibitors like cabozantinib—have shown promise by directly inhibiting aberrant signaling critical for tumor proliferation. Vascular endothelial growth factor (VEGF) inhibitors, which disrupt blood vessel formation that tumors need to grow, are also in the therapeutic arsenal. Moreover, immune checkpoint inhibitors, which unleash the immune system’s potential to recognize and attack cancer cells, have started reshaping the treatment paradigm.
Emerging clinical trials in 2024 suggest that combining MET TKIs with ICIs or VEGF inhibitors could offer synergistic effects, enhancing efficacy beyond monotherapies. Nevertheless, these combinations require rigorous evaluation of safety and tolerability before becoming standard care, highlighting the importance of continued research investment.
Alternative Approaches and When Surgery Isn’t an Option
Not all patients are surgical candidates due to multiple factors such as tumor spread, comorbidities, or patient preference. In such cases, less invasive methods provide hope and control options. Cryosurgery, which freezes tumor tissues, and thermal ablation techniques, using heat to destroy cancer cells, are minimally invasive options with potential to manage localized tumors or recurrences.
Renal artery embolization, which cuts off blood supply to the tumor, also serves as a palliative measure, particularly in controlling bleeding or pain. These alternatives, while not curative in all instances, demonstrate the growing arsenal available to personalize care and improve quality of life.
Outlook: Why Early Detection and Subtyping Matter
Survival rates for PRCC vary significantly by stage and subtype. Localized disease boasts a 5-year survival near 93%, compared to only 18% when the cancer has metastasized distantly. The indolent Type 1 variant generally yields better outcomes than the aggressive Type 2 subtype. This makes early diagnosis and accurate subtyping not mere academic concerns but vital clinical imperatives that can dictate prognosis and guide impactful treatment decisions.
Patients undergoing nephrectomy often adapt well with one kidney, but bilateral disease introduces greater complexity, frequently necessitating dialysis or transplant. This clinical reality further underscores the importance of advancements in systemic therapies that can control disease without complete reliance on surgical removal.
—
While PRCC might not dominate headlines like other cancers, its unique biology, treatment nuances, and evolving therapeutic landscape demand our focused attention. The trajectory of PRCC management is shifting from a one-size-fits-all approach to precision medicine fueled by molecular insights and innovative trials. This transformation fuels optimism—one that recognizes early detection, molecular targeting, and immune strategies as vital tools to improve outcomes for patients facing this challenging diagnosis.